ペプチド受容体核医学内用療法―Radio-Theranostics新時代への序章

Peptide receptor radionuclide therapy：a prologue of the way to the future of Radio-Theranostics

ペプチド受容体核医学内用療法（peptide receptor radionuclide therapy：PRRT）とPSMA治療（prostate spesific membrance antigen therapy）は，近年の核医学診療を使ったtheranostics（Radio-Theranostics）の代表格といえる治療である。PRRTは海外ではすでに切除不能神経内分泌腫瘍の標準治療の一つに位置づけられており，また，PSMA治療は前立腺癌の診療を今まさに塗り替えようとしている。本稿ではこれらの概説と，国内の現状についてご紹介したい。

Peptide receptor radionuclide therapy（PRRT）is a type of molecular-targeted internal radiation therapy that involves the use of a small peptide ligand coupled with a chelated beta-emitter, and it is regarded as a breakthrough of theranostics in nuclear medicine. The use of chelators allows not only visualization of the drug bio-distribution before therapy, but also adaptive synthesis, and small ligands allow drastic reduction of radiation exposure for normal tissues with rich blood flow because of its quick accumulation for tumors. This approach has already been applied to PSMA theranostics and is expected to apply other molecules rapidly. In this article, I will introduce the evidence from other countries and mention the domestic situation regarding PRRT.